Clinical trial
Molecular Profiling in Lung Cancer Patients
NCT00191308 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191308 |
|---|---|
| Title | Molecular Profiling in Lung Cancer Patients |
| Official title | Molecular Profiling and Safety Study of Operable Lung Cancer Patients Treated With Alimta Combined With Cisplatin as Neoadjuvant Chemotherapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer, Carcinoma |
| Intervention type | Drug, Procedure |
| Interventions | pemetrexed, cisplatin, Radical Non-Small Cell Lung Cancer (NSCLC) surgery |
| Enrollment | 30 |
| Start date | May 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Dec 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 21, 2011 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: